DA
ZVRA icon

DSC Advisors’s Zevra Therapeutics ZVRA Stock Holding History

DSC Advisors’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-131,700
Closed -$672K – 34
2023
Q2 		$672K Buy
+131,700
New +$710K 1.01% 10

Other funds holding ZVRA

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $40.4B AUM 21.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RPCONE
Retirement Planning Company of New England Warwick, Rhode Island $246M AUM 27.83% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
MAM
Mystic Asset Management Warwick, Rhode Island $431M AUM 25.35% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

DSC Advisors's ZVRA Position: Q3 2023 in Review

DSC Advisors sold out of Zevra Therapeutics (ZVRA) in Q3 2023, closing a stake of 49,100 shares — an estimated $250K sold.

DSC Advisors first reported a position in ZVRA in Q2 2015 and held it in 21 quarters. The position peaked at $15.9M in Q4 2015. 77 funds tracked by Wall St. Rank hold ZVRA as of Q3 2023.

  • DSC Advisors reported no remaining Zevra Therapeutics position as of Q3 2023 after selling out during the quarter.
  • DSC Advisors sold 49,100 Zevra Therapeutics shares in Q3 2023, an estimated $250K.
  • DSC Advisors first reported a position in Zevra Therapeutics in Q2 2015 and held it in 21 quarters.
  • DSC Advisors's Zevra Therapeutics position peaked at $15.9M in Q4 2015.
  • 77 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q3 2023.

Based on DSC Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.